AU2003281287A1 - Toxicity markers - Google Patents

Toxicity markers

Info

Publication number
AU2003281287A1
AU2003281287A1 AU2003281287A AU2003281287A AU2003281287A1 AU 2003281287 A1 AU2003281287 A1 AU 2003281287A1 AU 2003281287 A AU2003281287 A AU 2003281287A AU 2003281287 A AU2003281287 A AU 2003281287A AU 2003281287 A1 AU2003281287 A1 AU 2003281287A1
Authority
AU
Australia
Prior art keywords
toxicity markers
markers
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003281287A
Other versions
AU2003281287A8 (en
Inventor
Lasantha Ranasinghe-Bandara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0215575A external-priority patent/GB0215575D0/en
Priority claimed from GB0220879A external-priority patent/GB0220879D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2003281287A1 publication Critical patent/AU2003281287A1/en
Publication of AU2003281287A8 publication Critical patent/AU2003281287A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003281287A 2002-07-04 2003-07-04 Toxicity markers Abandoned AU2003281287A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0215575A GB0215575D0 (en) 2002-07-04 2002-07-04 Toxicity marker
GB0215575.2 2002-07-04
GB0220879A GB0220879D0 (en) 2002-09-09 2002-09-09 Toxicity markers
GB0220879.1 2002-09-09
PCT/GB2003/002893 WO2004005934A2 (en) 2002-07-04 2003-07-04 Toxicity markers

Publications (2)

Publication Number Publication Date
AU2003281287A1 true AU2003281287A1 (en) 2004-01-23
AU2003281287A8 AU2003281287A8 (en) 2004-01-23

Family

ID=30117095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003281287A Abandoned AU2003281287A1 (en) 2002-07-04 2003-07-04 Toxicity markers

Country Status (2)

Country Link
AU (1) AU2003281287A1 (en)
WO (1) WO2004005934A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
EP2479569A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
EP2240196A2 (en) * 2008-01-22 2010-10-20 Compugen Ltd. Clusterin derived peptide
CN102187220B (en) 2008-08-28 2015-08-19 阿斯图特医药公司 For the method and composition of diagnosis and prognosis injury of kidney and kidney failure
JP5947544B2 (en) 2008-08-29 2016-07-06 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2740788C (en) 2008-10-21 2023-03-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009313189B2 (en) * 2008-11-10 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462440B1 (en) 2009-08-07 2017-05-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013510322A (en) 2009-11-07 2013-03-21 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CN104698161A (en) 2009-12-20 2015-06-10 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9476868B2 (en) 2009-12-23 2016-10-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
CN102791885B (en) 2010-02-05 2015-09-09 阿斯图特医药公司 For the method and composition of the diagnosis and prognostic of injury of the kidney and renal failure
US9029093B2 (en) 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3339859A1 (en) 2010-06-23 2018-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2813851B1 (en) 2011-02-24 2016-06-08 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing kidney disorders in a feline
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RS57890B1 (en) * 2013-01-20 2019-01-31 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
WO2015157546A1 (en) 2014-04-09 2015-10-15 The Regents Of The University Of California Protein biomarkers for immune assessment and prediction of transplant rejection
JP6948265B2 (en) * 2015-04-30 2021-10-13 アイデックス ラボラトリーズ インコーポレイテッドＩＤＥＸＸ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． Specific detection of crusterin isoforms
US11244760B2 (en) 2015-06-25 2022-02-08 Karydo Therapeutix, Inc. Prediction device based on inter-organ cross talk system
EP3466446B1 (en) * 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
EP3438282A4 (en) * 2016-03-29 2020-05-06 Advanced Telecommunications Research Institute International Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405072A2 (en) * 2000-12-29 2004-04-07 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
WO2003019193A1 (en) * 2001-08-30 2003-03-06 Ciphergen Biosystems, Inc. Method of diagnosing nephrotic syndrome

Also Published As

Publication number Publication date
WO2004005934A3 (en) 2004-08-26
AU2003281287A8 (en) 2004-01-23
WO2004005934A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2003281287A1 (en) Toxicity markers
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
AU2003301443A1 (en) Azolecarboxamide herbicides
AU2002335152A1 (en) Robot-phone
WO2003072535A8 (en) Substituted hydroxyethylamines
AU2003275645A1 (en) Luminescents
AU2003238043A1 (en) Substituted imidazotriazines
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2003294900A1 (en) Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides
EP1314948A1 (en) Paintball markers
AU2003212366A1 (en) Substituted 4-aminocyclohexanols
AU2002367810A1 (en) Bis-transition-metal-chelate-probes
AU2003202012A1 (en) Toxicity test
AU2003246971A1 (en) Tranquilliser dart
AU2002318053A1 (en) Suplier
AU2002368348A1 (en) Electrosomatogram
AU2003218924A1 (en) Luminescent markers
AU2003236937A1 (en) School supply - universal
AU2002341221A1 (en) Honey-brandy
AU2002348964A1 (en) Snowbike
GB0220879D0 (en) Toxicity markers
AU2002344387A1 (en) Multifunction-pillow
GB0215577D0 (en) Toxicity marker
GB0215575D0 (en) Toxicity marker
AU2002100541A4 (en) Backmate

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase